-
Role of Non-Governmental Organizations in Canada's Access to Medicines Regime
The Government of Canada regards non-governmental organizations (NGOs) as valuable resources and actively consulted with them when designing Canada's Access to Medicines Regime. -
Health product advertising incidents related to COVID-19
Learn more about drugs and vaccines being developed or authorized for COVID-19. -
Moderna COVID-19 vaccine: Continued monitoring
At the time of authorization, no major safety concerns have been reported in the available data submitted to Health Canada. We are carefully monitoring the post-market (after... -
Clinical Trial Applications - process
This section explains in detail the process of preparation of an application, its submission, screening, evaluation, authorization/rejection, submission of amendments and post-... -
Instructions for the Canada Vigilance Adverse Reaction Online Database
The Canada Vigilance Adverse Reaction Online Database contains information on suspected adverse reaction reports related to marketed health products that were submitted to... -
Nutrient Value of Some Common Foods (T8)
The Nutrient Value of Some Common Foods (NVSCF) booklet. -
Décision d’homologation RD2019-12, 1-octanol et 1,4Zap
This decision is consistent with the Proposed Registration Decision PRD2019-03, Ammonium Salt of Fatty Acid, EMERION W 36 SL and AXXE Broad Spectrum Herbicide, which contains a... -
Transition Books for the Minister – Health Canada 2019
Overview of the Health Portfolio, issues/priorities for the first 100 days and a pocket book with Health Portfolio highlights. -
Health Product InfoWatch: November 2023
The following is a list of health product advisories, type I drug recalls and summaries of completed safety reviews published in October 2023 by Health Canada. -
2015 Dose Data from the Fixed Point Surveillance Network
The Fixed Point Surveillance (FPS) network monitors public radiation dose due to radioactive materials in the atmosphere. The FPS network is used primarily to measure the... -
Submitting risk management plans draft guidance document: RMP summary template
The RMP summary should include specific sections, which mirror the EU RMP Summary format sections. -
Guidance For Industry Management of Regulatory Submissions
This guidance document provides clarification to submission sponsors on how to comply with (Veterinary Drugs Directorate of Health Canada) VDD's policies, governing statutes and... -
Registration Decision RD2021-01, Trifludimoxazin, Vulcarus and Voraxor
This decision is consistent with the Proposed Registration Decision PRD2020-15, Trifludimoxazin, Vulcarus and Voraxor, which contains a detailed evaluation of the information... -
Consumer Product Safety Program Annual Surveillance Report: 2021
This report describes the surveillance findings gathered by the Consumer Product Safety Program (CPSP) within Health Canada -
Education modules to meet requirements for mandatory hospital reporting
Hospitals must report all serious adverse drug reactions (ADRs) and medical device incidents (MDIs). -
A Guide to Health Canada Inspections
Health Canada is responsible for many acts and their associated regulations that have a direct impact on the health and safety of Canadians. -
Health Canada’s Proposal to Update the Maximum Level for Total Arsenic in...
Food contaminants and other adulterating substances are chemicals that may be present in foods at levels that could impact the overall safety and/or quality of foods. These... -
Consumer Product Safety Program Annual Surveillance Report: 2018
This report describes the surveillance findings gathered by the Consumer Product Safety Program (CPSP) within Health Canada. The CPSP is responsible for the administration and... -
Applying for a Drug Identification Number (DIN) to distribute or sell hand...
Types of products eligible in receiving a Drug Identification Number (DIN).